European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative

Thumbnail
View/Open
Date
2019-09-05

Authors

Oppedal, Ketil
Borda, Miguel Germán
Ferreira, Daniel
Westman, Eric
Aarsland, Dag
The European DLB Consortium

Corporate Author(s)

Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Envejecimiento

Type

Artículo de revista

ISSN

1758-2024 / 1758-2032 (Electrónico)

Pages

247-250
Share this record
Gestores bibliográficos
Metadata
Show full item record
PDF documents

Abstract

As the population ages, the incidence of chronic diseases such as dementia increases. Dementia with Lewy bodies(DLB) is the second most common neurodegenerative dementia after Alzheimer’s disease (AD) and even thoughboth diseases are clinically separate entities.

Keywords

Biomarkers
Dementia with Lewy bodies
Diagnosis
E-DLB
European DLB consortium

Spatial coverage

Europa
Reino Unido

Link to the resource

https://www.futuremedicine.com/doi/10.2217/nmt-2019-0016?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov

DOI

https://doi.org/10.2217/nmt-2019-0016

URI

http://hdl.handle.net/10554/48473

Source

Neurodegenerative Disease Management; Vol. 9 Núm. 5 (2019)
Collections
Atribución-NoComercial 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución-NoComercial 4.0 Internacional